" class="no-js "lang="en-US"> Emmet O'Gara - Medtech Alert
Saturday, June 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Emmet O'Gara

Emmet O’Gara

About Emmet O’Gara

Experienced Healthcare Executive with a demonstrated history of working in health plans and the healthcare IT industry. Skilled in Enterprise Software, Sales, Operational Excellence, Healthcare Information Technology (HIT), and Management. Graduated from the University of New Hampshire with a degree in Health Management and Policy

Related Story

Appointments

 Sandata Announces Emmet O'Gara as New Chief Executive Officer | Pharmtech Focus

Sandata Announces Emmet O'Gara as New Chief Executive Officer

November 10 2021

Sandata is pleased to announce the appointment of Emmet O’Gara as the organization’s next Chief Executive Officer. […]